Skip to content Skip to footer
Subscribe Now
INSIGHTS+

Disease of the Month – Angina 

Shots:  Characterized by discomfort or pain in the chest, Angina develops when the heart does not receive adequate oxygen-rich blood  PharmaShots' Disease of the Month report aims to familiarize the general population with conditions impacting communities worldwide. The report outlines disease characteristics, types, symptoms, diagnosis, treatments, epidemiology, market size, clinical trial analysis, patient advocacy groups (PAGs),…
June 25, 2025

Read more

Atherosclerosis
INSIGHTS+

Disease of the Month – Atherosclerosis 

Shots:  Characterized by the thickening or hardening of arteries due to plaque buildup, atherosclerosis leads to complications like heart attack or stroke  PharmaShots' Disease of the Month report aims to familiarize the general population with conditions impacting communities worldwide. The report outlines disease characteristics, types, symptoms, diagnosis, treatments, epidemiology, market size, clinical trial analysis, patient…
May 28, 2025

Read more

Top Performing Drug of 2021 – Xarelto (November Edition)
INSIGHTS+

Top Performing Drug of 2021 – Xarelto (November Edition)

Active Ingredient: rivaroxaban  Strength: 2.5 mg, 10 mg, 15 mg, and 20 mg  Dosage Form: Tablets  Mechanism of Action: Factor Xa inhibitors  First Approval: US (1 Jul 2011), EU (30 Sep 2008)  Revenue Analysis of Xarelto1  Xarelto has been an important driver of the revenue generated from the cardiovascular portfolio of Janssen. The blood thinner showed an increase of 4%…
November 24, 2022

Read more

PharmaShots Interview Dr. R. Preston Mason, Consultant at Amarin, Corp. Shares Insights from its in vitro Study Results
VIEWPOINTS

PharmaShots Interview: Dr. R. Preston Mason, Consultant at Amarin, Corp. Shares Insights from its in vitro Study Results

Shots: Dr. Mason spoke about the key findings from their in vitro study demonstrating EPA + statins effects in reduced lipid oxidation, which were presented at the ACC 2022 He also spoke about the study design of the REDUCE-IT trial and its importance in the approval of its candidate in metabolic and cardiovascular diseases The interview summarizes…
August 3, 2022

Read more